Clinical Core

临床核心

• 批准号: 10413094
• 负责人: James McCallum Noble
• 金额: $ 87.37万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10413094
• 关键词: Address; African American population; Aging; Alzheimer' s Disease; Alzheimer' s Disease Pathway; Alzheimer' s disease related dementia; Area; Autopsy; Basic Science; Biological; Biological Markers; Blood; Blood Cells; Blood specimen; Brain; Brain imaging; Caregivers; Cells; Cerebrospinal Fluid; Cessation of life; Clinical; Clinical Data; Clinical Research; Clinical Trials; Code; Collaborations; Correlation Studies; DNA; Data; Data Collection; Data Coordinating Center; Data Element; Data Set; Database Management Systems; Dementia; Dementia with Lewy Bodies; Diagnosis; Diagnostic; Disease; Enrollment; Ensure; Environment; Evaluation; Extramural Activities; Family; Frontotemporal Dementia; Funding; Genetic; Genetic study; Goals; Hispanic Populations; Image; Imaging Device; Immunologics; Impaired cognition; Impairment; Individual; International; Interview; Liquid substance; Magnetic Resonance Imaging; Medical; Neurologic; Neuropsychological Tests; Neuropsychology; New York; Participant; Pathway interactions; Patient Recruitments; Peripheral Blood Mononuclear Cell; Persons; Pharmaceutical Preparations; Plasma; Population; Preparation; Quality Control; Randomized Clinical Trials; Research; Research Personnel; Resource Sharing; Resources; Sampling; Scientist; Site; Specific qualifier value; Specimen; Spinal Puncture; Students; Time; Tissues; Training; Translational Research; brain tissue; clinical center; cohort; data cleaning; data exchange; data management; data standards; ethnic diversity; improved; instrument; mild cognitive impairment; multi-ethnic; neuroimaging; neuroimmunology; neuropathology; outreach; patient engagement; ranpirnase; recruit; repository; research clinical testing; skills; social; symposium; training opportunity; transmission process

CLINICAL CORE PROJECT SUMMARY/ABSTRACT The Clinical Core is the central component of the P30 Alzheimer’s Disease Research Center (ADRC). The Clinical Core mandate is to provide resources to further the goals of the Center in understanding biological pathways of Alzheimer’s Disease. The Core is a shared resource interacting closely with: the Outreach, Recruitment, and Engagement Core (ORE) Core with regard to recruitment and training; the Database Management and Statistical (DMS) Core with respect to data entry, storage and management; the Neuropathology Core, through arranging brain autopsy and providing relevant correlative clinical data; and the Biomarker, Genetics, and Neuroimmunology Cores through provision of DNA, plasma, blood cells, and cerebrospinal fluid samples for biomarker, genetic, and immunological analyses. The Core will build upon its 29 years as a funded P50 ADRC, during which time it has enrolled more than 6,000 individuals, nearly 1,900 of which are in the NACC Uniform Data Set (UDS) – with ethnic diversity including about 20% Hispanics and 11% African Americans. The P30 Core will enroll 500 individuals in a new cohort: 100 new participants per year, including 25 normal controls, and 75 persons with mild cognitive impairment or dementia. These participants will each have extensive biomarker studies including research-grade 3T MRI, and lumbar puncture for cerebrospinal fluid studies, and be followed annually. The Core will provide data to the DMS Core, transmitted to the National Alzheimer’s Coordinating Center (NACC), and DNA for the Genetics Core, sent to the National Centralized Repository for Alzheimer’s Disease (NCRAD). Evaluations will include detailed medical and neurological interviews and examinations and neuropsychological testing, using NACC and Columbia site- specific instruments. Biomarkers will flow to Biomarker, Genetics, and Neuroimmunology Cores, including blood samples for plasma and peripheral blood cell populations, DNA preparation for genetic studies, CSF specimens for spinal fluid cells and fluid biomarkers, and 3T MRI neuroimaging. The Clinical Core goals include brain autopsies at the time of death, to provide neuropathological samples. The Core coordinates closely with Administrative, Biomarkers, DMS, ORE, Genetics, Neuroimmunology, and Neuropathology Cores, and with the REC module. Participants in the Core are informed of other trials and projects, and encouraged to participate in these important imaging, instrument, drug study, and biomarker trials. The Clinical Core provides training to students, residents, fellows, and investigators. Coded participant data, images, and biological specimens, including plasma, DNA, CSF, and brain tissue are shared with ADRC, and other Columbia and extramural investigators to improve diagnosis, understanding and treatment of aging and dementia, promoting basic and translational research at Columbia, in the New York area, nationwide, and internationally.

临床核心项目总结/摘要 临床核心是P30阿尔茨海默病研究中心（ADRC）的核心组成部分。的 临床核心任务是提供资源，以促进中心在了解生物学方面的目标。 阿尔茨海默病的发病机制核心是一种共享资源，与外展部门密切互动， 招聘和参与核心（ORE）招聘和培训方面的核心;数据库 管理和统计（DMS）核心数据输入，存储和管理; 神经病理学核心，通过安排脑尸检并提供相关的临床资料; 生物标志物，遗传学和神经免疫学核心，通过提供DNA，血浆，血细胞， 用于生物标志物、遗传学和免疫学分析的脑脊液样本。核心将建立在其 29年作为一个资助的P50 ADRC，在此期间，它已经招募了6,000多人，近1,900人， 这是在NACC统一数据集（UDS）-与种族多样性，包括约20%的西班牙裔和11%的 非裔美国人P30 Core将招募500名新参与者：每年100名新参与者， 包括25名正常对照者和75名轻度认知障碍或痴呆者。这些参与者 每个人都将进行广泛的生物标志物研究，包括研究级3 T MRI和腰椎穿刺， 脑脊液检查，并每年随访。核心将向DMS核心提供数据， 国家阿尔茨海默氏症协调中心（NACC）和遗传核心的DNA，送到国家阿尔茨海默氏症协调中心（NACC）。 阿尔茨海默病中央储存库（NCRAD）。评估将包括详细的医疗和 使用NACC和哥伦比亚网站进行神经病学访谈和检查以及神经心理学测试- 具体文书。生物标志物将流向生物标志物，遗传学和神经免疫学核心，包括 用于血浆和外周血细胞群的血液样本，用于遗传研究的DNA制备，CSF 用于脊髓液细胞和流体生物标志物的标本，以及3 T MRI神经成像。临床核心目标 包括死亡时的大脑解剖，以提供神经病理学样本。核心坐标 与管理、生物标志物、DMS、ORE、遗传学、神经免疫学和神经病理学核心密切合作， 还有REC模块核心项目的参与者被告知其他试验和项目，并被鼓励 参与这些重要的成像、仪器、药物研究和生物标志物试验。临床核心提供 对学生、住院医生、研究员和调查人员进行培训。编码的参与者数据、图像和生物信息 标本，包括血浆、DNA、CSF和脑组织与ADRC和其他哥伦比亚和 校外调查人员，以改善诊断，理解和治疗老化和痴呆症，促进 在哥伦比亚，在纽约地区，全国和国际的基础和转化研究。